Literature DB >> 6683174

Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols.

M A Blankenstein, G Blaauw, S W Lamberts, E Mulder.   

Abstract

The occurrence of oestrogen and progestin receptors in cytosols from human intracranial meningiomas was studied with a dextran-coated charcoal assay and Scatchard plot analysis. [3H]-Oestradiol and [3H]-promegestone (17 alpha, 21-dimethyl-19-norpregna-4,9-diene-3,20-dione, R-5020) were used as tracers. Using this method, no high-affinity binding sites for oestradiol were observed, whereas progestin binding was identified in 18 out of 20 meningioma cytosols. The number of progestin binding sites was identical in meningioma cytosols obtained from female patients (192 +/- 57 fmol/mg protein, mean +/- S.E.M., n = 12) and those obtained from male patients (230 +/- 57 fmol/mg protein, n = 6), as was the dissociation constant of the complex (1.5 +/- 0.3 vs 1.4 +/- 0.3 nmol/l respectively). Only progestins (progesterone, R-5020 and megestrol acetate) competed successfully with tritiated R-5020. Oestrogens, androgens and cortisol showed no appreciable cross-reaction. It was concluded that the cytosols from human intracranial meningiomas contain progesterone receptors in the absence of oestrogen receptors. The presence of these progesterone receptors may indicate that (anti)-progestational treatment could be of potential value in cases which cannot be treated by surgery alone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683174     DOI: 10.1016/0277-5379(83)90134-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  18 in total

Review 1.  Cervical lymph node metastases from remote primary tumor sites.

Authors:  Fernando López; Juan P Rodrigo; Carl E Silver; Missak Haigentz; Justin A Bishop; Primož Strojan; Dana M Hartl; Patrick J Bradley; William M Mendenhall; Carlos Suárez; Robert P Takes; Marc Hamoir; K Thomas Robbins; Ashok R Shaha; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-12-29       Impact factor: 3.147

2.  Immunocytochemical study of progesterone receptor in human meningioma.

Authors:  M Perrot-Applanat; M T Groyer-Picard; M Kujas
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

3.  Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.

Authors:  S M Grunberg; M H Weiss
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

4.  Expression of estrogen receptors alpha and beta in human meningiomas.

Authors:  R S Carroll; J Zhang; P M Black
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

5.  Mifepristone (RU 486) treatment of meningiomas.

Authors:  S W Lamberts; H L Tanghe; C J Avezaat; R Braakman; R Wijngaarde; J W Koper; H de Jong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

6.  Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma.

Authors:  J I Kuratsu; H Seto; M Kochi; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 7.  Epidemiology and etiology of intracranial meningiomas: a review.

Authors:  M Bondy; B L Ligon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

8.  Correlations of female steroid hormone receptors with histologic features in meningiomas.

Authors:  J Piquer; M Cerda; A Lluch; J L Barcia Salorio; J Garcia-Conde
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

9.  Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.

Authors:  J Jääskeläinen; E Laasonen; J Kärkkäinen; M Haltia; H Troupp
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

10.  A study on the biological behavior of human brain tumors. Part II: Steroid receptors and arachidonic acid metabolism.

Authors:  G Butti; P Gaetani; C Chiabrando; R Assietti; C Zibera; M G Castelli; N Gibelli; V Silvani; G Robustelli della Cuna; P Paoletti
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.